274 related articles for article (PubMed ID: 36560672)
1. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
Coffin CS; Haylock-Jacobs S; Doucette K; Ramji A; Ko HH; Wong DK; Elkhashab M; Bailey R; Uhanova J; Minuk G; Tsoi K; Wong A; Ma MM; Tam E; Brahmania M; Nudo C; Zhu J; Lowe CF; Osiowy C; Lethebe BC; Congly SE; Chan EKH; Villasis-Keever A; Sbarigia U; Cooper CL; Fung S
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560672
[TBL] [Abstract][Full Text] [Related]
2. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA.
Wang J; Zhu L; Zhang S; Zhang Z; Fan T; Cao F; Xiong Y; Pan Y; Li Y; Jiang C; Yin S; Tong X; Xiong Y; Xia J; Yan X; Liu Y; Liu X; Chen Y; Li J; Zhu C; Wu C; Huang R
Emerg Microbes Infect; 2024 Dec; 13(1):2339944. PubMed ID: 38584592
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers.
O'Neil CR; Congly SE; Rose MS; Lee SS; Borman MA; Charlton CL; Osiowy C; Swain MG; Burak KW; Coffin CS
Ann Hepatol; 2018; 17(2):232-241. PubMed ID: 31097238
[TBL] [Abstract][Full Text] [Related]
5. Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients.
Ahmed FA; Bajaifar MS; Ahmed MA; Alalwan A; Sanai FA; Albeladi K; Aljumah AA; Sanai FM
Saudi J Gastroenterol; 2019; 25(5):286-292. PubMed ID: 31044750
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
[TBL] [Abstract][Full Text] [Related]
7. Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients.
Wang CC; Tseng TC; Wang PC; Lin HH; Kao JH
J Formos Med Assoc; 2014 Nov; 113(11):786-93. PubMed ID: 23911291
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.
Tseng TC; Kao JH
J Gastroenterol; 2013 Jan; 48(1):13-21. PubMed ID: 23090000
[TBL] [Abstract][Full Text] [Related]
9. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
10. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
Chakrabarty G; Bruce M; Horner M; Wang B; Agarwal K; Carey I
J Viral Hepat; 2018 Jan; 25(1):80-87. PubMed ID: 28710798
[TBL] [Abstract][Full Text] [Related]
11. Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
Ungtrakul T; Sriprayoon T; Kusuman P; Chunnuan P; Soonklang K; Sornsamdang G; Auewarakul CU; Tanwandee T
Medicine (Baltimore); 2017 Mar; 96(13):e6554. PubMed ID: 28353619
[TBL] [Abstract][Full Text] [Related]
12. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
[TBL] [Abstract][Full Text] [Related]
13. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg).
Lim SG; Phyo WW; Ling JZJ; Cloherty G; Butler EK; Kuhns MC; McNamara AL; Holzmayer V; Gersch J; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lee YM; Lee GH; Tan PS; Huang DQ; Khine HTW; Lee C; Tay A; Chan E
Aliment Pharmacol Ther; 2021 Jan; 53(1):172-182. PubMed ID: 33159496
[TBL] [Abstract][Full Text] [Related]
14. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
[TBL] [Abstract][Full Text] [Related]
15. Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B.
Zhang M; Li J; Xu Z; Fan P; Dong Y; Wang F; Gao Y; Yan J; Cao L; Ji D; Feng D; Zhong Y; Zhang Y; Hong W; Zhang C; Wang FS
Hepatol Int; 2024 Apr; 18(2):435-448. PubMed ID: 38376650
[TBL] [Abstract][Full Text] [Related]
16. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
17. Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue.
Ramji A; Doucette K; Cooper C; Minuk GY; Ma M; Wong A; Wong D; Tam E; Conway B; Truong D; Wong P; Barrett L; Ko HH; Haylock-Jacobs S; Patel N; Kaplan GG; Fung S; Coffin CS
World J Gastroenterol; 2022 Aug; 28(31):4390-4398. PubMed ID: 36159017
[TBL] [Abstract][Full Text] [Related]
18. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
[TBL] [Abstract][Full Text] [Related]
19. Large spontaneous HBV DNA fluctuations and potential usefulness of a single-point measurement of combined HBV DNA and quantitative HBsAg for the exclusion of HBeAg-negative chronic hepatitis B: A prospective Tunisian cohort study.
Chtourou A; Gargouri S; Elleuch E; Feki L; Smaoui F; Taktak A; Mnif K; Kassis M; Hammami A; Ben Jemaa M; Karray H
Arab J Gastroenterol; 2023 Nov; 24(4):223-229. PubMed ID: 37989673
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis.
Jeng WJ; Chien RN; Chen YC; Lin CL; Wu CY; Liu YC; Peng CW; Su CW; Hsu CE; Liaw YF
Hepatology; 2024 Mar; 79(3):690-703. PubMed ID: 37625144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]